Michihiro Uchiyama
Suwa, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Diagnostic delay and clinical outcomes of paroxysmal nocturnal hemoglobinuria: a retrospective cohort study using Japanese claims data.
Journal: International journal of hematology
Published: March 04, 2026
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.
Journal: The Lancet. Haematology
Published: January 13, 2025
Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE Studies.
Journal: European journal of haematology
Published: August 14, 2024
Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in Japan.
Journal: International journal of hematology
Published: June 13, 2024
Patient perspectives on treatment for mantle cell lymphoma and chronic lymphocytic leukemia in Japan.
Journal: Journal of clinical and experimental hematopathology : JCEH
Published: May 15, 2024
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
Journal: The New England journal of medicine
Published: March 13, 2024
Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan.
Journal: International journal of hematology
Published: October 31, 2023
Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis.
Journal: Clinical lymphoma, myeloma & leukemia
Published: March 29, 2023
Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.
Journal: Hematological oncology
Published: August 23, 2022
Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study.
Journal: Japanese journal of clinical oncology
Published: April 10, 2022
Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis.
Journal: International journal of hematology
Published: February 15, 2022
Last Updated: 09/26/2026